Commentary

Article

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

State of the Science Summit - Breast Cancer: Chaired by Paolo Tarantino, MD, and Sara Tolaney, MD, MPH

Speakers

  • Adrienne Waks, MD | Dana-Farber Cancer Institute
  • Sarah Sammons, MD | Dana-Farber Cancer Institute
  • Erica Mayer, MD, MPH | Dana-Farber Cancer Institute
  • Filipa Lynce, MD | Dana-Farber Cancer Institute
  • Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute

Topics

  • Tailoring Treatment for HER2+ Early and Metastatic Breast Cancer
  • The Expanding Arsenal for Treating HR+/HER2- Metastatic Breast Cancer: CDK4/6i, PI3K/AKTi, SERDs and Beyond
  • Treatment of the Endocrine-Refractory Disease: Moving Beyond Traditional Chemotherapy
  • Evolving Trends in the (Neo)adjuvant Systemic Treatment of HR+/ HER2- Breast Cancer
  • Triple-Negative Breast Cancer: Targeting the Once Targetless Subtype
  • Targeting DNA Damage Response Pathways in Breast Cancer: Current Status, Opportunities and Pitfalls
  • On the Horizon: Novel Targets and Therapeutic Strategies in Breast Oncology

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Antonio Llombart-Cussac, MD, PhD
Joyce O'Shaughnessy, MD
Adrienne G. Waks, MD,
David Rimm, MD, PhD
This series features 2 KOLs
This series features 2 KOLs
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
4 KOLs are featured in this series.
4 KOLs are featured in this series.